Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aura Biosciences, Inc.

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Pricing of Initial Public Offering
From Aura Biosciences, Inc.
Via Business Wire
Tickers AURA
Aura Biosciences Announces Publication of Data in Cancer Immunology Research, Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform with Broad Application in Cancer Treatment
From Aura Biosciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.